Can Testosterone Increase Liver Enzymes?

Testosterone can increase liver enzymes, but whether it actually does depends almost entirely on the dose, the chemical form of the compound, and the person taking it. At the doses used in standard testosterone replacement therapy for men with low testosterone, liver enzymes generally stay flat or even drop. At the supraphysiological doses common in anabolic steroid abuse, liver enzyme elevations are well documented and sometimes dramatic. The relationship between testosterone and the liver is more layered than a simple yes-or-no, and the science in some areas runs counter to what most people expect.

Prescription Testosterone Replacement and Liver Enzymes

For men prescribed testosterone replacement therapy (TRT) by a doctor, the evidence on liver enzymes is reassuring. A systematic review and meta-analysis of randomized controlled trials in men with metabolic liver disease found that testosterone therapy actually produced a greater decrease in the liver enzymes AST, ALT, GGT, and ALP compared with placebo. The pooled changes showed reductions across all four markers, though confidence intervals were wide enough that some didn’t reach statistical significance.¹ That pattern, enzymes trending downward rather than upward, is the opposite of what many people fear when they hear “testosterone” and “liver” in the same sentence.

A two-year safety analysis of an oral testosterone undecanoate formulation in men with low testosterone found no clinically significant changes in ALT, AST, or bilirubin over the course of treatment. One participant had a single ALT spike above four times the upper limit of normal, but the level dropped on its own even though the person kept taking the medication. That was the only instance of a meaningful liver enzyme elevation in the entire study.² For men with liver cirrhosis, transdermal testosterone gel, which bypasses the liver’s first-pass metabolism entirely, appeared safe and well tolerated compared with other anabolic steroids.³

These findings don’t mean TRT is completely without hepatic considerations. Doctors still monitor liver function during treatment, and individual responses vary. But the broad pattern from clinical trials is that standard-dose testosterone replacement does not cause the kind of liver enzyme spikes people worry about.

Why Anabolic Steroid Abuse Is a Different Story

The picture changes sharply when testosterone or its synthetic derivatives are used at doses far above what the body naturally produces. A study comparing Saudi athletes using anabolic androgenic steroids (AAS) with non-users found statistically significant increases in both ALT and AST among the steroid users, along with a decrease in albumin and total bilirubin, all pointing toward liver stress.⁴ The researchers concluded that even short-term AAS use raised the risk of liver injury.

The types of liver damage linked to steroid abuse go beyond simple enzyme elevations. A review in the World Journal of Gastroenterology described how testosterone and its derivatives can cause cholestasis (a backup of bile flow), peliosis hepatis (blood-filled cavities in the liver), and both benign and malignant liver tumors. The mechanisms behind these injuries include disruption of antioxidant defenses, ramped-up bile acid production, and abnormal liver cell growth.⁵ These are serious conditions, not just numbers on a blood panel. Hepatocellular carcinoma, a form of liver cancer, has been documented in bodybuilders following prolonged AAS use, though such cases remain rare.⁶

The gap between therapeutic TRT and steroid abuse isn’t just about dose. It’s about the specific compounds. Many illicit AAS regimens involve multiple stacked substances, some of which are chemically modified in ways that make them far more toxic to the liver than bioidentical testosterone. That chemical distinction matters enormously.

The Chemical Structure That Makes Some Steroids Liver-Toxic

Not all testosterone-related compounds hit the liver the same way. The main culprits behind liver damage are 17-alpha-alkylated steroids, a class of oral anabolic compounds that have a methyl group added at the 17th carbon position. That structural tweak allows the drug to survive digestion and reach the bloodstream intact, but it also forces the liver to work much harder to process it. Classic examples include stanozolol (Winstrol), oxandrolone (Anavar), and methandrostenolone (Dianabol). These are the compounds behind most of the dramatic hepatotoxicity case reports in the medical literature.

Injectable testosterone (like testosterone cypionate or enanthate) and transdermal gels skip the liver’s first-pass metabolism, meaning they enter the bloodstream without the liver needing to break them down on the way in. That’s a major reason why prescription TRT, which overwhelmingly uses these delivery methods, has a far milder liver profile. Newer oral formulations of testosterone undecanoate are absorbed through the lymphatic system rather than the portal vein, which also reduces hepatic exposure. The two-year safety data on one such formulation confirmed no evidence of liver toxicity.⁷

So when someone asks whether testosterone raises liver enzymes, one of the most important clarifying questions is: which testosterone? A prescription gel or injection of bioidentical testosterone is pharmacologically worlds apart from a bottle of oral stanozolol bought from an underground lab. Lumping them together misrepresents the risk.

The Paradox of Low Testosterone and Liver Disease

Here’s where the story gets counterintuitive. Low testosterone in men is itself associated with fatty liver disease, the very condition that drives chronically elevated liver enzymes in millions of people. A study of men from the NASH Clinical Research Network found that about a quarter of men with non-alcoholic fatty liver disease (NAFLD) had low free testosterone. Those with low testosterone were more likely to have the inflammatory form of the disease (NASH) and advanced fibrosis than men with normal testosterone levels.⁸ Animal research has confirmed that testosterone deficiency worsens diet-induced fatty liver disease through specific cellular pathways.⁹

This creates an interesting clinical dynamic. Men with low testosterone are more likely to develop the metabolic conditions (visceral fat accumulation, insulin resistance, fatty liver) that elevate liver enzymes. Treating them with testosterone could, in theory, improve those metabolic parameters and bring enzymes down. Some data supports this. A long-term registry study following hypogonadal men for up to 12 years found that those receiving testosterone therapy showed decreases in their fatty liver index, GGT, bilirubin, and triglycerides over time.¹⁰ In men with type 2 diabetes, testosterone therapy produced a roughly 38% relative reduction in liver fat compared with placebo at 40 weeks.¹¹

Not every trial tells the same story, though. A randomized controlled trial of older hypogonadal men found no significant differences in NAFLD prevalence, liver fat on CT scan, or steatosis scores between the testosterone and placebo groups after 12 months.¹² The discrepancy likely reflects differences in the study populations, duration, and how fatty liver was measured. The evidence leans toward benefit in men who are both hypogonadal and metabolically unhealthy, but it isn’t unanimous.

Gender-Affirming Testosterone Therapy

Transgender men receiving testosterone as part of gender-affirming hormone therapy represent a large and well-studied group for this question. Reference interval studies have shown that liver enzymes (ALT, AST, ALP, GGT) tend to rise modestly in transgender men compared with cisgender female baselines, mirroring the sex-based differences seen in the general population, where men naturally have somewhat higher liver enzyme levels than women. These shifts are generally considered unlikely to be clinically meaningful, though they do have implications for interpreting lab results if a laboratory uses sex-specific reference ranges.¹³

A meta-analysis of 17 studies covering nearly 2,800 transgender men on testosterone found that gender-affirming therapy was associated with small, statistically significant increases in ALT at 3 to 12 months. The magnitude was modest: an increase of about 1 to 2 IU/L at the early timepoints, and no longer significant by 24 months. The prevalence of biochemical liver damage (defined as meaningfully elevated enzymes) was only about 1% across 14 studies.¹⁴ A separate longitudinal study concluded that the influence of long-term gender-affirming testosterone on ALT and AST appears modest and not likely to reflect clinically meaningful changes in liver function.¹⁵ A systematic review looking at testosterone therapy effects in transgender men reached a similar conclusion: six studies assessing liver function showed slight or no changes.¹⁶

One factor that may explain the slight enzyme shifts is liver mass. Men in the general population tend to have relatively larger livers than women, and testosterone therapy could plausibly nudge liver size upward over time. A larger liver with more metabolically active tissue would naturally produce slightly higher enzyme concentrations without any damage being present. This hasn’t been directly studied in the transgender population yet, but it’s a plausible explanation for modest increases that don’t reflect actual liver injury.¹³

Elevated Androgens in Women With PCOS

The testosterone-liver enzyme relationship runs in an interesting direction in women. Polycystic ovary syndrome (PCOS), which features higher-than-normal androgen levels, is associated with elevated liver enzymes. In Japanese women with PCOS, testosterone levels alongside BMI and blood glucose were strong predictors of who had elevated liver enzymes, with the combined model achieving good diagnostic accuracy.¹⁷ A separate study found that both ALT and AST were increased in women with PCOS, with a strong correlation between testosterone and AST levels.¹⁸

Research in young women with PCOS has shown that the degree of androgenicity, measured by the free androgen index, independently predicts elevated ALT even after accounting for age, obesity, insulin resistance, and dyslipidemia. Women in the highest quartile of free androgen index had the greatest risk of elevated ALT.¹⁹ This suggests that in women, excess testosterone can drive liver enzyme elevations through pathways that are at least partially independent of the usual metabolic suspects like obesity and insulin resistance.

The contrast with men is striking. In men, low testosterone is linked to worse liver health, and restoring normal levels may help. In women, excess testosterone is linked to worse liver health. The relationship between androgens and the liver appears to be sex-specific, with an optimal range that differs between men and women.

How Quickly Liver Enzymes Recover After Stopping Steroids

For people who have used anabolic steroids and are concerned about liver enzyme elevations, the recovery timeline is generally encouraging. A study of bodybuilders who had used androgenic-anabolic steroids found that three months after stopping, their liver enzymes (alkaline phosphatase and GGT) were within the normal range and showed no differences compared with bodybuilders who had never used steroids.²⁰ The liver is famously good at regenerating, and for most people who stop the offending substance, enzyme levels normalize relatively quickly.

That said, recovery from structural liver damage is a different matter. Cholestasis usually resolves, but conditions like peliosis hepatis (where blood-filled cysts form in the liver tissue) and hepatic tumors can persist or progress even after cessation. The distinction between reversible enzyme elevations and irreversible tissue damage is one reason that using liver enzymes alone as a monitoring tool during steroid abuse gives false reassurance. Enzymes reflect what’s happening right now; they don’t capture cumulative damage well. Someone could have normal enzyme levels while harboring a liver adenoma that developed during a previous cycle.

When to Be Concerned About Your Labs

If you’re on prescription TRT and your doctor orders liver function tests, a small shift in ALT or AST from one visit to the next is rarely cause for alarm. The key question is whether your values have moved outside the normal reference range and whether they stay there. A single mildly elevated reading often resolves on its own. The two-year oral testosterone safety study, for instance, documented only one transient spike above four times the upper limit of normal across the entire trial, and it came back down without intervention.⁷

Guidelines for gender-affirming hormone therapy mention a risk of liver injury within the first months of treatment with anabolic androgenic steroids, though the clinical evidence in transgender populations at therapeutic doses suggests this concern is somewhat overstated.²¹ Routine monitoring is still reasonable, especially in the first year of therapy or in people with pre-existing liver conditions, but the data don’t support anxiety about routine testosterone use causing progressive liver damage.

The situation where liver enzyme monitoring becomes genuinely critical is unsupervised AAS use, particularly with oral 17-alpha-alkylated compounds. If you’re using these, persistently elevated enzymes (especially if ALT or AST climbs above three times the upper limit of normal) deserve prompt medical evaluation. Yellowing of the skin or eyes, dark urine, or right-upper-quadrant pain are signs of more advanced liver involvement that warrant immediate attention, regardless of what your last enzyme panel showed. Enzymes lag behind damage in some forms of steroid-induced liver injury, so symptoms matter as much as numbers.

1
PubMed Central. The Effects of Testosterone Replacement Therapy in Adult Men With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-analysis
2
Endocrine Practice. Safety and Efficacy of a Novel Oral Testosterone Undecanoate Formulation in Hypogonadal Men
3
PubMed. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis
4
ScienceDirect / Saudi Pharmaceutical Journal. The assessment of liver function test and fertility hormones in Saudi athletes using anabolic androgenic steroids
5
PubMed Central. Anabolic androgenic steroid-induced liver injury: An update
6
PubMed Central. Hepatocellular carcinoma in body builders; an emerging rare but serious complication of androgenic anabolic steroid use
7
PubMed Central. Safety Analysis of an Oral Testosterone Undecanoate (TU) Formulation Following 2 Years of Administration in Hypogonadal Men
8
Frontiers in Endocrinology. Androgen dysfunction in non-alcoholic fatty liver disease: Role of sex hormone binding globulin
9
PubMed. Testosterone deficiency aggravates diet-induced non-alcoholic fatty liver disease by inducing hepatocyte ferroptosis via targeting BMAL1 in mice
10
PubMed. Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study
11
PubMed Central. Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations
12
The Journal of Clinical Endocrinology & Metabolism. The Effect of Testosterone Replacement Therapy on Nonalcoholic Fatty Liver Disease in Older Hypogonadal Men
13
The Journal of Applied Laboratory Medicine. Reference Intervals for Clinical Chemistry Analytes for Transgender Men and Women on Stable Hormone Therapy
14
PubMed Central. Biochemical liver damage during gender affirming therapy in trans adults assigned female at birth: a meta-analysis
15
PubMed Central. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy
16
PubMed. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review
17
PubMed Central. Prevalence and Risk Factors of Elevated Liver Enzymes in Japanese Women With Polycystic Ovary Syndrome
18
PubMed. Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome
19
The Journal of Clinical Endocrinology & Metabolism. Hyperandrogenemia Is Independently Associated with Elevated Alanine Aminotransferase Activity in Young Women with Polycystic Ovary Syndrome
20
PubMed. Body composition, cardiovascular risk factors and liver function in long-term androgenic-anabolic steroids using bodybuilders three months after drug withdrawal
21
European Journal of Endocrinology. Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy?